PHASE III IGRT AND SBRT VS IGRT AND HYPOFRACTIONATED IMRT FOR LOCALIZED INTERMEDIATE RISK PROSTATE CANCER

Disease (cancer type)

Prostate Cancer

Contact information

  • Michigan: Maria Pappas (248) 553-0606

Patient Selection Criteria

Previously untreated localized adenocarcinoma of the prostate with the following clinical findings: Clinical stage by digital rectal exam of either T1c or T2a/b (limited to one side of the gland). (AJCC, version 7) or cT1a-c or 2a or 2b, Stage Group IIA or IIB (AJCC, version 8). Both versions 7 and 8 staging should be recorded. Patients in active surveillance who elect to be treated are eligible if they meet protocol requirements Stages T1a-T1b are eligible if patient underwent TURP previously Gleason score must be Gleason 7(3+4) with a PSA < 20 ng/mL, or Gleason 6(3+3) with a PSA > 10 ng/mL and < 20 ng/mL. (AJCC, version 7) or Group Grade 1 or 2, Stage Group IIA or IIB (AJCC version 8) o If patient

Research sponsor

NRG/NCI

Reference ID#

GU005

State(s)

  • Michigan
Back
To top